The review criterion is proposed in this combined notice, rather than individual program announcements, to provide consistent review of all primary care medical education grant applications. An announcement will be made in the *HRSA Preview* for grant programs which will conduct competitive cycles in FY 1998.

The comment period is 30 days. All comments received on or before October 3, 1997 will be considered before the final review criteria are established. Written comments should be addressed to: Enrique Fernandez, M.D., Division of Medicine, Bureau of Health Professions, Health Resources and Services Administration, Parklawn Building, Room 9A–20, 5600 Fishers Lane, Rockville, Maryland 20857, Telephone: (301) 443–1467, FAX: (301) 443–8890.

All comments received will be available for public inspection and copying at the Division of Medicine, at the above address, weekdays (Federal holidays excepted) between the hours of 8:30 a.m. and 5:00 p.m.

Dated: August 28, 1997.

Claude Earl Fox,

Acting Administrator. [FR Doc. 97–23373 Filed 9–2–97; 8:45 am] BILLING CODE 4160–15–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting of the National Cancer Institute Special Emphasis Panel (SEP) meeting:

Name of SEP: Cancer Prevention Control and Surveillance.

Date: September 15, 1997. Time: 1 p.m. to adjournment.

Place: Teleconference, Executive Plaza North, Conference Room E, 6130 Executive Boulevard, Bethesda, MD 20852.

Contact Person: Courtney M. Kerwin, Ph.D., M.P.H., Scientific Review Administrator, National Cancer Institute, NIH, Executive Plaza North, Room 630I, 6130 Executive Boulevard, MSC 7410, Bethesda, MD 20892–7410, Telephone: 301/496–7421.

Purpose/Agenda: To evaluate and review responses to Request for Proposal.

This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

The meeting will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Proposal and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the proposal, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. (Catalog of Federal Domestic Assistance Program Numbers: 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control)

Dated: August 26, 1997.

LaVeen Ponds,

Policy Analyst, NIH, CMO. [FR Doc. 97–23284 Filed 9–2–97; 8:45 am] BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Cancer Institute Special Emphasis Panel (SEP) meeting:

Name of SEP: Evaluation of Chemopreventive Agents by In vitro Techniques.

Date: September 11–12, 1997. Time: 9 a.m. to 5 p.m.

Place: Ramada Inn-Rockville, 1775 Rockville Pike, Rockville, MD 20852.

Contact Person: Lalita Palekar, Ph.D., Scientific Review Administrator, National Cancer Institute, NIH, 6130 Executive Boulevard, North, Room 622B, Bethesda, MD 20892–7410, Telephone: 301/496–7575.

Purpose/Agenda: To evaluate and review responses to a Request for Proposal.

This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

The meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5 U.S.C. Proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. (Catalog of Federal Domestic Assistance Program Numbers: 93.393, Cancer Cause and

Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control)

Dated: August 26, 1997.

LaVeen Ponds,

Policy Analyst, National Institutes of Health, Committee Management Office. [FR Doc. 97–23285 Filed 9–2–97; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Cancer Institute Special Emphasis Panel (SEP) meeting:

Name of SEP: Clinical/Experimental Radiation Research Studies (CERRIS). Date: October 5–6, 1997.

Time: October 5—7:30 p.m. to 11 p.m.; October 6—8 a.m. to 6 p.m.

Place: The Bethesda Ramada Hotel, 8400 Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: Kevin Ryder, Ph.D., Scientific Review Administrator, National Cancer Institute, NIH, Executive Plaza North, Room 611D, 6130 Executive Boulevard, MSC 7410, Bethesda, MD 20892–7410, Telephone: 301/402–2785.

Purpose/Agenda: To evaluate and review a grant application.

The meeting will be closed in accordance with the provision set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5 U.S.C. Application and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the application, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Numbers: 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control)

Dated: August 26, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, National Institutes of Health.

[FR Doc. 97-23287 Filed 9-2-97; 8:45 am]

BILLING CODE 4140-01-M